Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Professor Anthony Axon
- Incidences and mortality of cancer types
- Scanning EM of Helicobacter pylori
- Aims of this presentation
- Transmission EM of Helicobacter pylori
- Acute infection with H. pylori
- Biopsies of acute gastric inflammation
- Chronic gastritis with "activity" in the antrum
- Helicobacter gastritis before and after treatment
- H. pylori gastric mucosa interactions
- Atrophy and intestinal metaplasia after infection
- H. pylori, gastric atrophy and IM over time
- Natural history of Hp Gastritis
- Hp as an essential risk factor for gastric cancer
- Association between Hp and gastric cancer
- Problems with IgG ELISA serology
- Gastric cancer and Hp - corrected for CagA
- Helicobacter gastritis and gastric acidity (1)
- Type of gastritis and cancer risk
- Corpus atrophy in gastric cancer
- Conclusive flow chart
- H. pylori infection in animal models
- H. pylori and gastric cancer - summary
- Mechanisms involved in gastric carcinogenesis
- Does Hp itself directly cause gastric cancer?
- The Correa hypothesis
- Epithelial cell proliferation and Hp eradication
- Gastric ascorbic acid conc. and Hp eradication
- Reactive oxygen species in H, pylori gastritis
- Effect of treatment
- Stem cells
- Bone marrow derived cells
- Bone marrow derived cells and gastric cancer
- New model for gastric cancer development
- Appreciate why gastric cancer incidence varies
- World map of gastric cancer mortality
- Why does gastric cancer vary in incidence?
- Hp and the socio-economically disadvantaged
- Japanese versus British gastritis
- Comparison of gastritis in matched populations
- IM and atrophy in matched populations
- Differing gastritis patterns in Japan and England
- Difference in diet
- Dietary factors influence on gastric cancer
- Effects of the CagA pathogenicity island
- Non-cardia cancer and Hp genotypes
- Genetics and gastric cancer
- Proinflammatory cytokine gene polymorphisms
- Hp and host genetics and carcinogenic effects
- Helicobacter gastritis and gastric acidity (2)
- Inflammation in the corpus and acid secretion
- Corpus atrophy after acid suppression treatment
- Increasing acid secretion in Japan
- Acid secretion is related to lean body mass
- Increasing height of men in Europe 1960-1990
- Immune experience
- Summary
Topics Covered
- Helicobacter pylori (Hp) and gastric cancer
- Natural history of Hp gastritis
- Hp as an essential risk factor
- Mechanisms of carcinogenesis
- Why the variation in cancer incidence?
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Axon, A. (2011, May 9). Gastric cancer, gastritis and the role of H. pylori [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/GJOA2654.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Anthony Axon has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.